Literature DB >> 22031268

Three polymorphisms of the eNOS gene and plasma levels of metabolites of nitric oxide in depressed Japanese patients: a preliminary report.

Atsuko Ikenouchi-Sugita1, Reiji Yoshimura, Taro Kishi, Wakako Umene-Nakano, Hikaru Hori, Kenji Hayashi, Asuka Katsuki, Nobuhisa Ueda, Nakao Iwata, Jun Nakamura.   

Abstract

BACKGROUND: Depression is a risk factor for coronary heart disease. Nitric oxide (NO) plays an important role in both coronary heart disease and depression.
METHODS: Fifty-one inpatients and outpatients who met the Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition criteria for major depressive disorder (MDD) in the university hospital of the University of Occupational and Environmental Health and 58 age-matched and sex-matched healthy controls enrolled in this study. We investigated the association between the three polymorphisms of the endothelial nitric oxide synthase (eNOS) gene (single-nucleotide polymorphism (SNP); rs2070744, rs1799983, variable number tandem repeat (VNTR) in intron 4) and scores on the Hamilton Rating Scale for Depression, plasma metabolites of NO (NO(x) ) or ankle brachial index in patients with MDD and healthy controls.
RESULTS: We did not find significant differences in the genotype distributions between patients with MDD and healthy volunteers. No associations were observed between any of the polymorphisms of the eNOS gene and the Hamilton Rating Scale for Depression or ankle brachial index in patients with MDD. However, plasma NO(x) level was significantly associated with a polymorphism of the eNOS gene (rs207044 and variable number tandem repeat in intron 4).
CONCLUSION: These results suggest that the direct association was not observed between the polymorphisms of the eNOS gene and the pathogenesis of depression.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22031268     DOI: 10.1002/hup.1239

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  7 in total

1.  The role and mechanism of asymmetric dimethylarginine in fetal growth restriction via interference with endothelial function and angiogenesis.

Authors:  Yan Dai; Jun Zhang; Rong Liu; Na Xu; Song-Biao Yan; Yi Chen; Tian-He Li
Journal:  J Assist Reprod Genet       Date:  2020-03-25       Impact factor: 3.412

2.  Determination of Endothelial Nitric Oxide Synthase Gene Polymorphism and Plasma Asymmetric Dimethyl Arginine Concentrations in Patients with Lung Cancer.

Authors:  Zafer Bayraktutan; Ahmet Kiziltunc; Ebubekir Bakan; Hamit Hakan Alp
Journal:  Eurasian J Med       Date:  2020-06-05

Review 3.  Genetic Factors of Nitric Oxide's System in Psychoneurologic Disorders.

Authors:  Regina F Nasyrova; Polina V Moskaleva; Elena E Vaiman; Natalya A Shnayder; Nataliya L Blatt; Albert A Rizvanov
Journal:  Int J Mol Sci       Date:  2020-02-26       Impact factor: 5.923

4.  Vasovagal Syncope Is Associated with Variants in Genes Involved in Neurohumoral Signaling Pathways.

Authors:  Boris Titov; Natalya Matveeva; Olga Kulakova; Natalia Baulina; Elizaveta Bazyleva; Grigory Kheymets; Anatolii Rogoza; Alexander Pevzner; Olga Favorova
Journal:  Genes (Basel)       Date:  2022-09-15       Impact factor: 4.141

5.  The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction.

Authors:  Yiming Wang; Xingde Liu; Dongfeng Zhang; Jianhui Chen; Shuzheng Liu; Michael Berk
Journal:  BMC Med       Date:  2013-02-08       Impact factor: 8.775

6.  A Meta-Analysis of Oxidative Stress Markers in Depression.

Authors:  Tao Liu; Shuming Zhong; Xiaoxiao Liao; Jian Chen; Tingting He; Shunkai Lai; Yanbin Jia
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 7.  Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence.

Authors:  Souhel Najjar; Daniel M Pearlman; Orrin Devinsky; Amanda Najjar; David Zagzag
Journal:  J Neuroinflammation       Date:  2013-12-01       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.